Article

Stem cell research may hold key to restoring neural function in glaucoma patients

At this time there is no therapy that can restore vision after retinal ganglion cell (RGC) death in patients with glaucoma. However, stem cell-based treatments do have the potential to restore function in individuals with various neurodegenerative diseases, reported Keith R. Martin, MD, of Cambridge University, Cambridge, England, at the annual meeting of the Association for Research in Vision and Ophthalmology.

May 4

- Fort Lauderdale, FL - At this time there is no therapy that can restore vision after retinal ganglion cell (RGC) death in patients with glaucoma. However, stem cell-based treatments do have the potential to restore function in individuals with various neurodegenerative diseases, reported Keith R. Martin, MD, of Cambridge University, Cambridge, England, at the annual meeting of the Association for Research in Vision and Ophthalmology.

In a video of a mice study, researchers demonstrated that stem cells could be used to restore function in the spinal cord, allowing paralyzed mice to walk again. So, could this possibly translate to the eye, restoring visual function? Dr. Martin believes so.

"We need to try to find and stimulate an endogenous stem cell population within the eye," he said. "Or we can try to persuade mature cells to dedifferentiate and redifferentiate as retinal ganglion cells."

The best candidates for retinal "stem cells" are the Muller cells. These cells can express markers for mature retinal neurons and can migrate to the RGC layer, he said.

"Muller progenitor cells injected subretinally have been shown to incorporate into the retina of immunosuppressed RCS rats and to preserve visual function," Dr. Martin explained.

However, researchers using stem cells are faced with challenges, such as:

• stem cells expressing all the right markers may not function;

• stem cells aging;

• rejection; and

• tumor risk.

"Our growing understanding of stem cell biology holds promise of completely new treatment strategies to protect and restore visual function in patients with glaucoma," he noted.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.